Wellfully Limited

Equities

WFL

AU0000105033

Biotechnology & Medical Research

Delayed Australian S.E. Other stock markets 01:02:13 2023-07-21 am EDT			5-day change	1st Jan Change
0.003 ^AUD	-.--%		-.--%	-.--%

Apr. 08	Wellfully Limited Reports Earnings Results for the Half Year Ended December 31, 2023	CI
Feb. 29	Wellfully Limited Reports Earnings Results for the Full Year Ended June 30, 2023	CI

Wellfully Limited Reports Earnings Results for the Full Year Ended June 30, 2022

August 31, 2022 at 03:34 am EDT

Wellfully Limited reported earnings results for the full year ended June 30, 2022. For the full year, the company reported sales was AUD 2.6 million compared to AUD 1.2 million a year ago. Net loss was AUD 8.07 million compared to AUD 6.4 million a year ago.

Basic loss per share from continuing operations was AUD 0.0338 compared to AUD 0.041 a year ago.

Latest news about Wellfully Limited

Wellfully Limited Reports Earnings Results for the Half Year Ended December 31, 2023	Apr. 08	CI
Wellfully Limited Reports Earnings Results for the Full Year Ended June 30, 2023	Feb. 29	CI
Wellfully Limited Announces Bill Pavlovski Steps Down from His Role as Non-Executive Director	23-06-20	CI
Wellfully Limited Announces Board Changes	23-06-09	CI
Wellfully Limited Appoints John Forrester as Director	23-05-17	CI
Wellfully Limited Announces Address Changes	23-05-10	CI
Wellfully Receives R&D Tax Refund	23-04-27	MT
Wellfully Completes AU$1.5 Million Placement	23-04-06	MT
Wellfully Limited Reports Earnings Results for the Half Year Ended December 31, 2022	23-04-05	CI
Wellfully Limited Announces Executive Changes	23-03-22	CI
Wellfully Limited Advises Delayed in Reporting its Financial Results for the Six Month Period Ended 31 December 2022	23-02-26	CI
Wellfully Limited announced that it expects to receive AUD 0.26 million in funding from Celtic Capital Pty. Ltd.	23-01-22	CI
Wellfully Limited Appoints David Wheeler as Non-Executive Director, Effective from 1 February 2023	23-01-09	CI
Wellfully Secures Convertible Loan	22-12-29	MT
Wellfully Taps Consulting Firm to Assist in Frankfurt Dual Listing	22-12-29	MT
Wellfully Limited Announces Step Down of Steven Schapera as Non-Executive Director, Effective 31 December 2022	22-12-29	CI
Wellfully Signs Pact to Merge Wellness Marketing Company with Self	22-12-06	MT
Wellfully Limited entered into a non-binding memorandum of understanding to acquire The Brandbase from Capital D Management LLP for AUD 2.8 million.	22-12-05	CI
Wellfully Limited Appoints Andy Wortlock as Non-Executive Director	22-11-18	CI
Wellfully Seeks Extension of Voluntary Suspension	22-11-16	MT
Wellfully Temporarily Halts Trading	22-11-14	MT
Wellfully Issues More Than 21 Million Ordinary Shares	22-11-04	MT
Wellfully's Lugano-based Facility Receives GMP Certification	22-10-02	MT
Wellfully Limited's Swiss Facility Receives GMP Certification	22-10-02	CI
Wellfully Limited Auditor Raises 'Going Concern' Doubt	22-10-01	CI

Chart Wellfully Limited

Duration

Period

More charts

Company Profile

Wellfully Limited is an Australia-based fully integrated, science-based wellness company. The Company has developed physical enhancement technologies based on the interactions between ingredient molecules and weak atomic forces. Its brands include REDUIT and SWISSWELL. Its REDUIT brand designs technology-enhanced skincare and haircare treatments, and its technologies include ultrasonic diffusion and magnetic misting. SWISSWELL is a biotechnology brand that offers a technology-enhanced joint management system, the Swisswell Knee Patch. Swisswell is an adhesive knee patch worn on the knee to lubricate the joint before, during and after physical activity. It also offers a portfolio of technologies and support partners by providing Internet Protocol (IP) and has capabilities in magnetic array design, and claims testing, engineering and production. It is focused on both large and small companies across a range of market sectors, including cosmetics and skincare, and consumer healthcare.

Sector

Biotechnology & Medical Research

Calendar

2025-02-25 - Q2 2025 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
WELLFULLY LIMITED	-.--%	989K
MODERNA, INC.	+33.63%	50.93B
IQVIA HOLDINGS INC.	-0.09%	42.12B
LONZA GROUP AG	+49.62%	42.05B
CELLTRION, INC.	-4.96%	29.18B
ICON PUBLIC LIMITED COMPANY	+11.18%	26.02B
ALNYLAM PHARMACEUTICALS, INC.	-21.95%	18.9B
BIO-TECHNE CORPORATION	+8.61%	13.21B
UNITED THERAPEUTICS CORPORATION	+24.73%	12.17B
MEDPACE HOLDINGS, INC.	+28.31%	12.16B

Other Biotechnology & Medical Research